


# CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, \* $\theta$ DLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

## Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

### A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (*Duarte, CA, USA*)

Molecular Mechanisms of Action of Imatinib Mesylate in Human Ovarian Cancer: A Proteomic Analysis. B.B. PATEL, Y.A. HE, X.-M. LI, A. FROLOV, L. VANDERVEER, C. SLATER, R.J. SCHILDER, M. VON MEHREN, A.K. GODWIN, A.T. YEUNG (*Philadelphia, PA; Birmingham, AL, USA*)

Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (*Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA*)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (*Kiel; Tuebingen, Germany*)

Immune Response Signatures of Benzo( $\alpha$ )pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (*Morgantown, WV, USA*)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (*Uppsala; Stockholm, Sweden*)

Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. I.L. BOTCHKINA, R.A. ROWEHL, D.E. RIVADENEIRA, M.S. KARPEH Jr., HOWARD CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, G.I. BOTCHKINA (*San Francisco, CA; Stony Brook, New York, NY, USA*)

Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (*Giessen, Germany*)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (*Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA*)

A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Poststate Cancer. P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, H.M. COLEY (*Surrey, UK*)

Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (*Cardiff, UK*)

Down-regulation of Microfilament Network-Associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnostics. M. BRAUN, M. FOUNTOULAKIS, A. PAPAPOULOU, K. VOUGAS, I. SEIDEL, T. HÖLLER, K. YEGHIAZARYAN, H.H. SCHILD, W. KUHN, O. GOLUBNITSCHAJA (*Bonn, Germany; Athens, Greece*)

Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (*Stony Brook, NY, USA*)

online from January 2009



**in vivo**

International Journal of Experimental and Clinical  
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN: 0258-851X

### General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

### Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)

### Selection of Recent Articles

Investigation of the Effects of Aging on Homologous Recombination in Long Term Bone Marrow Cultures. M.W. EPPERLY, R. RUGO, S. CAO, H. WONG, D. FRANICOLA, J.P. GOFF, H. SHEN, X. ZHANG, D. WIKTOR-BROWN, B.P. ENGELWARD, J.S. GREENBERGER (*Pittsburgh, PA; Cambridge, MA, USA*)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (*Zellik; Brussels; Vilvoorde, Belgium*)

Failure of  $\alpha$ -Galactosylceramide to Prevent Diabetes in Virus-Inducible Models of Type 1 Diabetes in the Rat. P. CHOPRA, P. DI IORIO, S.C. PINO, S.B. WILSON, N.E. PHILLIPS, J.P. MORDES, A.A. ROSSINI, D.L. GREINER, L.D. SHULTZ, R. BORTELL (*Worcester; Cambridge, MA; Bar Harbor, ME, USA*)

Drug Resistance of Human Immunodeficiency Virus and its Overcoming by Natural Products, A Review. J. HUPFELD, T. EFFERTH (*Heidelberg, Germany*)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increases Adenoma and flat ACF Number in the Intestine of *Min/+* mice. C. RÖNNINGBORG, T. HUSØY, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*)

Distribution of [ $^3$ H]corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats after Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKUHL, J. HAU (*Uppsala, Sweden; Copenhagen, Denmark*)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism, and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NÚÑEZ, S.D. HURSTING, S.N. PERKINS (*Austin; Smithville, TX; Bethesda, MD, USA*)

*In Vivo* Studies on the Availability and Toxicity of Antisense-oligonucleotides in Bladder Cancer. C.E. BLIETZ, B. THODE, M. HAUSES, R. PRIES, A.J. MEYER, C. DOEHN, D. JOCHAM, I. KAUSCH (*Lübeck; Leipzig, Germany*)

Auricular Chondrocytes – From Benchwork to Clinical Applications. C. NABZDYK, J. MOLINA, E. PERIN, D. PANIAGUA, D. ROSENSTRAUCH (*Berlin, Germany; Houston, TX, USA*)

Effects of Neonatal Administration of Diethylstilbestrol on Aberrant Crypt Foci Induced by 7,12-Dimethylbenz[ $\alpha$ ]anthracene in Rats. H. KAWASHIMA, H. KAWAGUCHI, Y. UMEKITA, M. SOUDA, K. GEJIMA, T. KOMOKATA, R. SAKATA, H. YOSHIDA (*Kagoshima, Japan*)

MnSOD Genotype and Prostate Cancer Risk as a Function of NAT Genotype and Smoking Status. T. IGUCHI, S. SUGITA, C.Y. WANG, N.B. NEWMAN, T. NAKATANI, G.P. HAAS (*Syracuse, NY, USA; Osaka, Japan*)

Selective Anti-bacterial and Apoptosis-modulating Activities of Mastic. H. SAKAGAMI, K. KISHINO, M. KOBAYASHI, K. HASHIMOTO, A. SHIMETANI, Y. NAKAMURA, K. TAKAHASHI, T. IKARASHI, H. FUKAMACHI, K. SATOH, H. NAKASHIMA, T. SHIMIZU, K. TAKEDA, S. WATANABE, W. NAKAMURA (*Saitama; Fukushima; Tokyo; Kanagawa; Chiba, Japan*)

Immunohistochemical Staining of Mucin 1 in Prostate Tissues. N. RABIAU, P. DÉCHELOTTE, L. GUY, S. SATHI, R. BOSVIEL, L. FONTANA, J.-L. KEMENY, J.-P. BOITEUX, Y.-J. BIGNON, D. BERNARD-GALLON (*Clermont-Ferrand, France*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# Subscription Order Form 2009

- Please enter a Subscription to ANTICANCER RESEARCH for Volume 29 (2009).  
 Annual subscription rates (2009): Institutional, Euro 1,612.00 - online; 1,634.00 - print; 1,682.00 - print & online.  
 Personal, Euro 763.00 - online; 785.00 - print; 833.00 - print & online. Prices include rapid delivery and insurance.
- Please send me the following previous volumes (1-28) at 50% discount on the above rates:
- Payment is enclosed.  Please invoice.  
 (Cheques should be made payable to J.G. Delinassios, Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....

Tel: .....

Fax: ..... e-mail: .....

Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

## Special 2009 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2009 on a basis of priority and availability. Effective from January to December 2009).



Your link to the essential information on cancer research published in the last 28 years.

- 1981-2008
- 28 volumes
- over 81,000 pages
- over 12,500 original articles
- 571 reviews
- over 53,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:  
 ANTICANCER RESEARCH Editorial Office, International Institute of Anticancer Research,  
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

### Special Subscription Order Form 2009

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2009 (Volume 29) at the special Author's rate of Euro 417.00 (print or online); Euro 500.00 (print & online).
- Please send me previous Volume No(s) ..... at Euro 208.00 per volume.
- Please enter my personal combined 2009 subscription to Anticancer Research (Volume 29), IN VIVO (Volume 23) and CANCER GENOMICS & PROTEOMICS (Volume 6) at Euro 755.00 (print or online); Euro 972.00 (print & online).
- My payment is enclosed.
- Please send me an invoice.  
 (Prices include rapid delivery and insurance. Cheques should be made payable to J.G. Delinassios, Athens, Greece).

Name and address: .....

Tel-Fax: .....

e-mail: .....

Date and signature: .....

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept high quality original works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority should be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) announcements of meetings related to cancer research; (c) short reviews (of approximately 1,200 words) and announcements of newly published books and journals related to cancer; and (d) announcements of awards and prizes.

The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in AR, for public archiving in PubMed Central.

A main aim of AR is to ensure the prompt publication of high quality original works, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on cancer that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts in terms of grammar and style.

*Format.* Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all the essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, indication of the study type "clinical", "epidemiological", or "experimental", and date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

*Tables.* Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*References.* Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. *In: Receptors for Reproductive Hormones.* O' Malley BW and Chamnes GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

*Submission of Manuscripts.* You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. **OR** You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS. 1st km Kapandritiou-Kalamou Road, P.O. Box 22, GR-19014, Kapandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each published article will be provided free-of-charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Cardiopulmonary Response to Exercise in Patients with Different Degrees of Lung Toxicity after Radio-chemotherapy for Hodgkin's Disease. F. VILLANI, A. BUSIA, M. VILLANI, A. LAFFRANCHI, S. VIVIANI, V. BONFANTE ( <i>Milan, Italy</i> ) .....	777
p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up. G.E. THEODOROPOULOS, E. KARAFOKA, J.G. PAPAILIOU, P. STAMOPOULOS, C.P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, J. BRAMIS ( <i>Athens, Greece</i> ) .....	785
Errata .....	793

\* Review (pages 605, 631, 753)

GnRH Receptor and Androgen Receptor Status and Outcome of Advanced Prostate Carcinomas. J. SZABÓ, K. BARTÓK, T. KRENÁCS, Z. SZEPEŠVÁRY, B. SZENDE ( <i>Budapest, Hungary</i> ) .....	681
Wall-invasion Pattern Correlates with Survival of Patients with Gallbladder Adenocarcinoma. K.-I. OKADA, H. KIJIMA, T. IMAIZUMI, K. HIRABAYASHI, M. MATSUYAMA, N. YAZAWA, Y. OIDA, S. DOWAKI, K. TOBITA, Y. OHTANI, M. TANAKA, S. INOKUCHI, H. MAKUUCHI ( <i>Kanagawa; Aomori, Japan</i> ) .....	685
Effects of Epoetin- $\alpha$ on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy. C. CHRISTODOULOU, U. DAFNI, G. ARAVANTINOS, A. KOUTRAS, E. SAMANTAS, M. KARINA, J. JANINIS, P. PAKOSTAS, D. SKARLOS, H.P. KALOFONOS, G. FOUNTZILAS ( <i>Athens; Patras; Thessaloniki, Greece</i> ) .....	693
The Potential Role of Bcl-2 Expression, Apoptosis and Cell Proliferation (Ki-67 Expression) in Cases of Gastric Carcinoma and Correlation with Classic Prognostic Factors and Patient Outcome. A.C. TSAMANDAS, D. KARDAMAKIS, P. TSIAMALOS, A. LIAVA, V. TZELEPI, V. VASSILIOU, T. PETSAS, K. VAGENAS, V. ZOLOTA, C.D. SCOPA ( <i>Patras, Greece</i> ) .....	703
Initial Results of Colorectal Polyposis Research in Latvia. V. BOROŠENKO, A. IRMEJS, I. MELBĀRDEGORKUŠA, A. GARDOVSKIS, M. PAVĀRS, A. VANAGS, G. TROFIMOVIČS, E. MIKLAŠEVIČS, J. GARDOVSKIS ( <i>Riga, Latvia</i> ) .....	711
Preliminary Study of TIP47 as a Possible New Biomarker of Cervical Dysplasia and Invasive Carcinoma. A. SZIGETI, O. MINIK, E. HOCSAK, E. POZSGAI, A. BORONKAI, R. FARKAS, A. BALINT, J. BODIS, B. SUMEGI, S. BELYEI ( <i>Pécs, Hungary</i> ) .....	717
Lung Cancer Susceptibility and Genetic Polymorphisms of <i>Exo1</i> Gene in Taiwan. N.-Y. HSU, H.-C. WANG, C.-H. WANG, C.-F. CHIU, H.-C. TSENG, S.-Y. LIANG, C.-W. TSAI, C.-C. LIN, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	725
Angiogenic Factors in Plasma of Brain Tumour Patients. A. ILHAN, W. GARTNER, D. NEZIRI, T. CZECH, W. BASE, W.H. HÖRL, L. WAGNER ( <i>Vienna, Austria</i> ) .....	731
Analysis of 7 Immunohistochemical Markers in Male Germ Cell Tumors Demonstrates the Prognostic Significance of p53 and MIB-1. D. PECTASIDES, G. PAPAXOINIS, M. NIKOLAOU, C. VALAVANIS, G. ARAVANTINOS, G. FOUNTZILAS, N. TAMVAKIS, E. PECTASIDES, I. LEKKA, P. ARAPANTONIDADIOTI, A. ZIZI, I. GHICONTI, T. ECONOMOPOULOS ( <i>Athens; Piraeus; Thessaloniki, Greece</i> ) .....	737
Epithelial Ovarian Cancer in Greece: A Retrospective Study of 1,791 Patients by the Hellenic Cooperative Oncology Group (HeCOG). D. PECTASIDES, G. PAPAXOINIS, G. FOUNTZILAS, G. ARAVANTINOS, A. BAMIAS, N. PAVLIDIS, H.P. KALOFONOS, E. TIMOTHEADOU, E. SAMANTAS, E. BRIASOULIS, D.V. SKARLOS, T. ECONOMOPOULOS, M.A. DIMOPOULOS ( <i>Athens; Thessaloniki; Ioannina; Patras; Piraeus, Greece</i> ) .....	745
* Genetic Polymorphisms of Smoking-related Carcinogen Detoxifying Enzymes and Head and Neck Cancer Susceptibility. M. LACKO, M.B. OUDE OPHUIS, W.H.M. PETERS, J.J. MANNI ( <i>Maastricht; Nijmegen, The Netherlands</i> ) .....	753
Recently Intensified Chemotherapy for High-grade Osteosarcoma May Affect Fertility in Long-term Male Survivors. T. YONEMOTO, T. ISHII, Y. TAKEUCHI, Y. HAGIWARA, S. IWATA, S.-I. TATEZAKI ( <i>Chiba; Japan</i> ) .....	763
Combination Chemotherapy with Docetaxel, Vinorelbine and Estramustine Phosphate in Metastatic Androgen-resistant Prostate Cancer: A Single Institution Experience. D. PECTASIDES, E. PECTASIDES, G. PAPAXOINIS, A. KOUMARIANOU, A. PSYRRI, N. XIROS, N. TOUNTAS, K. KAMPOSIORAS, G. PAPATSIBAS, T. FLOROS, P. GOVERIS, S. KARAGEORGOPOULOU, T. ECONOMOPOULOS ( <i>Athens, Greece</i> ) .....	769

Validity of Hepatic Resection of Colorectal Liver Metastases in the Elderly (75 Years and Older). K. NOJIRI, Y. NAGANO, K. TANAKA, K. MATSUO, S. YAMAGISHI, M. OTA, S. FUJII, C. KUNISAKI, S. TOGO, H. SHIMADA ( <i>Yokohama, Japan</i> ) .....	583
Correlation of Metallothionein Expression with Clinical Progression of Cancer in the Oral Cavity. J. SZELACHOWSKA, P. DZIEGIEL, J. JELEN-KRZESZEWSKA, M. JELEN, R. TARKOWSKI, B. SPYTKOWSKA, R. MATKOWSKI, J. KORNAFEL ( <i>Wroclaw; Poznan, Poland</i> ).....	589
The Combination of Low Cytoplasmic and High Nuclear Expression of p27 Predicts a Better Prognosis in High-grade Astrocytoma. T. HIDAKA, S. HAMA, P. SHRESTHA, T. SAITO, Y. KAJIWARA, F. YAMASAKI, K. SUGIYAMA, K. KURISU ( <i>Hiroshima, Japan</i> ) .....	597
* Chronic Lymphocytic Leukaemia. J. BOELEN, S. LUST, B. VANHOECKE, F. OFFNER ( <i>Ghent, Belgium</i> ) .....	605
Association of Metastin/a G-protein-coupled Receptor Signaling and Down Syndrome Critical Region 1 in Epithelial Ovarian Cancer. K. HATA, Y. WATANABE, H. NAKAI, T. MINAMI, H. OHSAKI, E. HIRAKAWA, H. HOSHIAI ( <i>Takamastu; Osaka-Sayama; Tokyo, Japan</i> ) .....	617
Phase II Study of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer in Japan. J. Horiguchi, Y. RAI, K. TAMURA, T. TAKI, K. HISAMATSU, Y. ITO, T. SERIU, T. TAJIMA ( <i>Gunma; Kagoshima; Fukuoka; Osaka; Hiroshima; Ariake, Japan; Princeton, NJ, USA</i> ) .....	625
* Therapy-induced Toxicity of the Lungs: An Overview. A.G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K.D. DILANA, E.M. KARAPANAGIOTOU, K.N. SYRIGOS ( <i>Athens, Greece</i> ).....	631
Circulating Vascular Endothelial Growth Factors and their Soluble Receptors in Pre-invasive, Invasive and Recurrent Cervical Cancer. S. KUEMMEL, A. THOMAS, S. LANDT, A. FUGER, P. SCHMID, M. KRINER, J.-U. BLOHMER, J. SEHOULI, G. SCHALLER, W. LICHTENEGGER, A. KÖNINGER, I. FUCHS ( <i>Essen; Berlin; Munich, Germany; London, UK</i> ).....	641
Characterization of a MAGE-1-derived HLA-A24 Epitope-specific CTL Line from a Japanese Metastatic Melanoma Patient. Y. AKIYAMA, K. MARUYAMA, S. TAI, M. KOMIYAMA, A. IIZUKA, M. TAKIKAWA, C. OHSHITA, A. YAMAMOTO, N. YAMAZAKI, Y. KIYOHARA, K. YAMAGUCHI ( <i>Shizuoka; Saitama; Tokyo, Japan</i> ) .....	647
Further Studies Support the Participation of Stem Cells in the Cell Turnover of Duodenal Adenomas. C.A. RUBIO ( <i>Stockholm, Sweden</i> ) .....	657
Efficacy of Concurrent Chemoradiotherapy for T1 and T2 Laryngeal Squamous Cell Carcinoma Regarding Organ Preservation. G. NISHIMURA, M. TSUKUDA, Y. MIKAMI, H. MATSUDA, C. HORIUCHI, T. TAGUCHI, M. TAKAHASHI, M. KAWAKAMI, M. WATANABE, T. NIHO, H. ABO, S. YAMOMOTO ( <i>Yokohama, Japan</i> ) .....	661
A Phase II Trial of Oral Vinorelbine and Capecitabine in Anthracycline Pretreated Patients with Metastatic Breast Cancer. J. FINEK, L. HOLUBEC JR., T. SVOBODA, L. SEFRHANSOVA, I. PAVLIKOVA, M. VOTAVOVA, M. SEDIVA, S. FILIP, R. KOZEVNIKOVA, S. KORMUNDA ( <i>Pilsen; Prague; Hradec Kralove, Czech Republic</i> ).....	667
Procollagen Type 1 Amino-terminal Propeptide: A Marker for Bone Metastases in Prostate Carcinoma. M. KLEPZIG, D. JONAS, G.M. OREMEK ( <i>Frankfurt/Main, Germany</i> ) .....	671
Successful Treatment with Three-weekly Paclitaxel of an Anthracycline-refractory Classical Kaposi's Sarcoma. N. SILVESTRIS, D. GALETTA, G. COLUCCI ( <i>Bari, Italy</i> ).....	675
First Report of Liposarcoma of the Spermatic Cord after Radical Prostatectomy for Prostate Cancer. T. YOSHINO, K. YONEDA, T. SHIRANE ( <i>Hiroshima, Japan</i> ) .....	677

Intravenous Leiomyomatosis of the Uterus with Pulmonary Metastases or a Case with Benign Metastasizing Leiomyoma? B. BODNER-ADLER, M. BARTL, G. WAGNER ( <i>Vienna, Austria</i> ) .....	495
Malignant Myoepithelioma in the Maxillary Sinus: Case Report and Review of the Literature. M. HATA, K. TOKUUYE, Y. SHIOYAMA, S. NOMOTO, Y. INADOME, N. FUKUMITSU, H. NAKAYAMA, S. SUGAHARA, K. OHARA, M. NOGUCHI, Y. AKINE ( <i>Yokohama, Kanagawa; Tsukuba, Ibaraki; Fukuoka, Fukuoka, Japan</i> ) .....	497
Concomitant Right Subscapular and Left Olecranon Elastofibroma Followed by Inversion of the Lesions: Case Report. M. MAZZOCCHI, A. MARTANO, S. DI RONZA, E. DODBIBA, L. DIVONA, N. SCUDERI ( <i>Perugia; Rome, Italy</i> ) .....	503
Overexpression of Cytochrome P450 1B1 in Advanced Non-small Cell Lung Cancer: A Potential Therapeutic Target. J.-M. SU, P. LIN, C.-K. WANG, H. CHANG ( <i>Taichung; Miaoli, Taiwan, ROC</i> ) .....	509
Neoadjuvant Weekly Paclitaxel with and without Trastuzumab in Locally Advanced or Metastatic Breast Cancer. J. Horiguchi, T. Oyama, Y. Koibuchi, T. Yokoe, D. Takata, F. Ikeda, H. Nagaoka, N. Rokutanda, R. Nagaoka, Y. Ishikawa, H. Odawara, M. Kikuchi, A. Sato, Y. Iino, I. Takeyoshi ( <i>Gunma; Tochigi; Takasaki; Ogawa, Japan</i> ) .....	517
Development of Gastro-lymphatic Fistula During Chemoradiotherapy for Advanced Esophageal Cancer: A Case Report. G. Kasuya, K. Ogawa, H. Shimoji, W. Tamaki, H. Karimata, T. Toita, Y. Kakinozana, T. Ariga, T. Nishimaki, S. Murayama ( <i>Okinawa, Japan</i> ) .....	525
Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck. G. Fountzilias, A. Bamiyas, A. Kalogera-Fountzila, G. Karayannopoulou, M. Bobos, E. Athanassiou, K.T. Kalogeras, C. Tolis, P. Tsekiris, P. Papakostas, C. Vamvouka, T. Zaramboukas, P. Kosmidis, N. Zamboглу, D. Misailidou ( <i>Thessaloniki; Athens, Greece; Offenbach, Germany</i> ) .....	529
Concomitant Overexpression of Heat-shock Protein 70 and HLA Class-I in Hepatitis C Virus-related Hepatocellular Carcinoma. S. Yoshida, S. Hazama, K. Tokuno, K. Sakamoto, M. Takashima, T. Tamesa, T. Torigoe, N. Sato, M. Oka ( <i>Ube, Yamaguchi; Sapporo, Japan</i> ) .....	539
Clinicopathological Prognostic Factors and Patterns of Recurrence in Vulvar Cancer. L. Woelber, S. Mahner, K. Voelker, C.Z. Eulenburg, F. Giesecking, M. Choschzick, F. Jaenicke, J. Schwarz ( <i>Hamburg, Germany</i> ) .....	545
Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors. J.-P. Delord, C. Puzzo, F. Lefresne, R. Bugat ( <i>Toulouse; Boulogne Billancourt, France</i> ) .....	553
Favourable Prognosis with Modified Dosing of Docetaxel and Cisplatin in Japanese Patients with Ovarian Cancer. D. Aoki, Y. Watanabe, T. Jobo, K. Ushijima, K. Hasegawa, N. Susumu, N. Suzuki, R. Aoki, S. Isonishi, S. Sagae, B. Ishizuka, T. Kamura, Y. Udagawa, H. Hoshiai, Y. Ohashi, K. Ochiai, K. Noda ( <i>Tokyo; Osaka; Kanagawa; Fukuoka; Aichi; Hokkaido, Japan</i> ) .....	561
Immunotherapy in Patients with Less than Complete Response to Chemotherapy. F. Recchia, G. Candeloro, S. Neozione, R. Biseigna, M. Bratta, S. Rea ( <i>Avezzano; Rome; L'Aquila, Italy</i> ) .....	567
Test of Ovarian Cancer Multiplex xMAP Technology Panel. J. Vrzalova, M. Prazakova, Z. Novotny, O. Topolcan, M. Casova, L. Holubec Jr. ( <i>Prague; Pilsen, Czech Republic</i> ) .....	573
Outpatient Chemotherapy with S-1 for Recurrent Head and Neck Cancer. T. Yamashita, S. Shinden, T. Watabe, A. Shiotani ( <i>Saitama; Tochigi, Japan</i> ) .....	577